From: Pharmacological basis and clinical evidence of dabigatran therapy
Advantages over VKA | Disadvantages over VKA |
---|---|
No need of periodic INR control | High prize |
Lower interactions | Not indicated in renal disease |
Favorable safety versus efficacy profile, it may reduce VKA misdosing | No antidote and lack of experience in hemorrhage complications |